MIH
KROS icon

Meitav Investment House’s Keros Therapeutics KROS Stock Holding History

Meitav Investment House’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,597
Closed -$63.8K – 446
2023
Q2 		$63.8K Buy
+1,597
New +$70K ﹤0.01% 420
2023
Q1 		– Sell
-17,475
Closed -$841K – 370
2022
Q4 		$841K Hold
17,475
– – 0.01% 258
2022
Q3 		$634K Hold
17,475
– – 0.01% 273
2022
Q2 		$482K Sell
17,475
-95,644
-85% -$4.2M 0.01% 277
2022
Q1 		$6.15M Sell
113,119
-24,517
-18% -$1.26M 0.09% 146
2021
Q4 		$8M Hold
137,636
– – 0.13% 129
2021
Q3 		$5.45M Buy
+137,636
New +$4.9M 0.09% 155

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Meitav Investment House's KROS Position: Q3 2023 in Review

Meitav Investment House sold out of Keros Therapeutics (KROS) in Q3 2023, closing a stake of 1,597 shares — an estimated $63.8K sold.

Meitav Investment House first reported a position in KROS in Q3 2021 and held it in 7 quarters. The position peaked at $8M in Q4 2021. 107 funds tracked by Wall St. Rank hold KROS as of Q3 2023.

  • Meitav Investment House reported no remaining Keros Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Meitav Investment House sold 1,597 Keros Therapeutics shares in Q3 2023, an estimated $63.8K.
  • Meitav Investment House first reported a position in Keros Therapeutics in Q3 2021 and held it in 7 quarters.
  • Meitav Investment House's Keros Therapeutics position peaked at $8M in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2023.

Based on Meitav Investment House's 13F filing for Q3 2023, filed 30 Oct 2023.